TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Wolf Haldenstein Adler Freeman & Herz Llp
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

Telix Pharmaceuticals faces a securities class action lawsuit alleging misrepresentations about its prostate cancer therapeutic candidates and supply chain operations, with stock price drops following SEC subpoena and FDA Complete Response Letter.

Insights
AAPL   positive

Second largest holding for FIRETRAIL Investments, representing approximately 8.8% of the fund's assets under management


TLX   negative

Company experienced significant stock price declines after SEC subpoena and FDA Complete Response Letter, indicating potential misrepresentations about drug pipeline and operational progress